Cargando…

Higher nuclear EGFR expression is a better predictor of survival in rectal cancer patients following neoadjuvant chemoradiotherapy than cytoplasmic EGFR expression

The aim of the present study was to investigate the prognostic value of cytoplasmic (−C) and nuclear epidermal growth factor receptor (EGFR-N) expression in rectal cancer patients following neoadjuvant concurrent chemoradiotherapy (CCRT). A total of 172 newly diagnosed rectal cancer patients post-ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Ching-Chieh, Lin, Li-Ching, Lin, Yu-Wei, Tian, Yu-Feng, Lin, Chen-Yi, Sheu, Ming-Jen, Li, Chien-Feng, Tai, Ming-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341901/ https://www.ncbi.nlm.nih.gov/pubmed/30675212 http://dx.doi.org/10.3892/ol.2018.9756

Ejemplares similares

High Expression of Aldolase B Confers a Poor Prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy
por: Tian, Yu-Feng, et al.
Publicado: (2017)

High Expression of EphA4 Predicted Lesser Degree of Tumor Regression after Neoadjuvant Chemoradiotherapy in Rectal Cancer
por: Lin, Ching-Yih, et al.
Publicado: (2017)

Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy
por: Lee, Yi-Ying, et al.
Publicado: (2017)

High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy
por: Chen, Tzu-Ju, et al.
Publicado: (2018)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Usefulness of close surveillance for rectal cancer patients after neoadjuvant chemoradiotherapy
por: Hsu, Yu-Jen, et al.
Publicado: (2022)

High neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy
por: Ke, Te-Min, et al.
Publicado: (2020)

The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Meng, Xiangjiao, et al.
Publicado: (2014)

Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer
por: Huang, Yan, et al.
Publicado: (2019)

Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy
por: Wang, Hui-Ching, et al.
Publicado: (2019)

Machine learning for predicting pathological complete response in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy
por: Huang, Chun-Ming, et al.
Publicado: (2020)

High Immunoreactivity of DUOX2 Is Associated With Poor Response to Preoperative Chemoradiation Therapy and Worse Prognosis in Rectal Cancers
por: Lin, Shih-Chun, et al.
Publicado: (2017)

Outcomes of neoadjuvant chemoradiotherapy followed by radical resection for T4 colorectal cancer
por: Huang, Chun-Ming, et al.
Publicado: (2020)

HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
por: Chou, Chia-Wei, et al.
Publicado: (2011)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis
por: Kuo, Yu-Hsuan, et al.
Publicado: (2022)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma
por: Pu, Yeong-Shiau, et al.
Publicado: (2009)

Pretreatment Neutrophil-to-Lymphocyte Ratio Associated with Tumor Recurrence and Survival in Patients Achieving a Pathological Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer
por: Huang, Chun-Ming, et al.
Publicado: (2021)

Restaging rectal cancer following neoadjuvant chemoradiotherapy
por: Cuicchi, Dajana, et al.
Publicado: (2023)

Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis
por: Lai, I-Li, et al.
Publicado: (2023)

Critical reappraisal of neoadjuvant concurrent chemoradiotherapy for treatment of locally advanced colon cancer
por: Chen, Yen-Cheng, et al.
Publicado: (2021)

Survival-associated factors of first-line EGFR-tyrosine kinase inhibitor responders and non-responders in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2018)

Prognostic significance of lung radiation dose in patients with esophageal cancer treated with neoadjuvant chemoradiotherapy
por: Lin, Jhen-Bin, et al.
Publicado: (2019)

Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy
por: Shim, Byoung Yong, et al.
Publicado: (2016)

Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity
por: Wang, Chia-Chun, et al.
Publicado: (2014)

Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy?
por: Chong, Yousun, et al.
Publicado: (2014)

Sustaining the Activation of EGFR Signal by Inflammatory Cytokine IL17A Prompts Cell Proliferation and EGFR-TKI Resistance in Lung Cancer
por: Lee, Kai-Ling, et al.
Publicado: (2023)

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction
por: Wu, Shang-Gin, et al.
Publicado: (2011)

The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma
por: Richter, Igor, et al.
Publicado: (2015)

Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
por: Wei, Yu-Feng, et al.
Publicado: (2019)

Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy
por: Xiao, Lin, et al.
Publicado: (2016)

Optimal Lymph Node Yield for Survival Prediction in Rectal Cancer Patients After Neoadjuvant Therapy
por: Lin, Yu-Min, et al.
Publicado: (2021)

Prognostic and staging value of tumor deposits in patients with rectal cancer after neoadjuvant chemoradiotherapy
por: Xu, Tianlei, et al.
Publicado: (2021)

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
por: Chang, Cheng-Yu, et al.
Publicado: (2021)

Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors
por: Wu, Shou-Cheng, et al.
Publicado: (2016)

Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?
por: Yeh, Jen-Hao, et al.
Publicado: (2022)

Upregulated Ubiquitin D is a Favorable Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy
por: Chou, Chia-Lin, et al.
Publicado: (2022)

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
por: Martinez-Useros, J., et al.
Publicado: (2018)

Pretreatment TACC3 expression in locally advanced rectal cancer decreases the response to neoadjuvant chemoradiotherapy
por: Ma, Wen-juan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kss355430rhikrf5fd838smtgg